Thursday, August 10, 2017 4:27:59 AM
There is much competition for Aptose to fight against in the “finding the cure for cancer” market. From a business perspective, having a drug that cures cancer will practically print money for them. For example, some treatments for cancer can cost from $3000 too much more. These drugs, depending on their effectiveness, can create profits in the $1 Billion+ region. Because of this, many institutions are putting funds into finding the cure for various forms of cancer. This market is contently changing with new discoveries being frequently made. From a business standpoint, you need to make a drug that is more efficient, more effective, and more cost-effective to sell to the public. Simply, if you make the better drug and sell it for cheaper, your business will gain the market.
Looking at Aptoses’ income statement, they have a running loss with $0 in revenue. For the first quarter of 2017, the company had a net loss of ~$4,355,000. Also, over the course of the last year, the company has had a net loss of ~$17,910,000. Unless the company can create and sell one of their cures, Aptose will continue to run at a loss. If the company was to sell one of their cures, it comes down to how effective and efficient the drug is. These medicines would help it penetrate a full cancer treatments market. There is the possibility that the drugs and treatments could sell very well, but there is serious doubt that such an event will happen.
Aptoses’ balance statement shows that it has ~11,958,000 in on hand cash Q1 2017. From what we were able to find, the company is gaining on-hand cash from selling company shares to investors. In total, Aptose has a total of ~$12,676,000 in assets for Q1 2017. For accounts payable, Aptose has ~$2,340,000 in current liabilities. For shareholders equity, investors of Aptose have ~$235,869,000 in shares. The accumulated deficit for investors is ~$247,877,000.
Read More Here
Recent APTO News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 08:15:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2024 08:20:21 PM
- Aptose Announces Results from Special Meeting of Shareholders • GlobeNewswire Inc. • 09/05/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2024 08:35:07 PM
- Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib • GlobeNewswire Inc. • 08/30/2024 08:30:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/15/2024 08:35:12 PM
- Aptose Announces Adjournment of its Special Meeting of Shareholders • GlobeNewswire Inc. • 08/15/2024 08:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 09:22:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 09:15:13 PM
- Aptose Reports Results for the Second Quarter 2024 • GlobeNewswire Inc. • 08/08/2024 09:06:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/26/2024 08:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2024 09:00:14 PM
- Aptose Announces Receipt of Deficiency Notice from Nasdaq • GlobeNewswire Inc. • 07/19/2024 09:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 07/17/2024 03:43:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 11:40:15 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 08:35:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 02:32:05 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/03/2024 10:05:42 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 12:05:15 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/15/2024 03:47:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 09:06:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:15:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 03:35:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 08:45:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 10:00:16 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM